Background: Intra-operative radiation therapy (IORT) is the transfer of a single large radiation dose to the tumor bed during surgery with the final goal of improving regional tumor control. This study aimed to investigate the safety, effectiveness and economic evaluation of intra-operative radiation therapy.
Introduction
Cancer is commonly used for great group of diseases that can influence any part of the body. One of the specifications defining cancer includes fast reproduction of abnormal cells beyond their regular duplication that can attack their neighborhood sides and diffuse to other organs of the body. This is called metastasis. Metastasis is the main cause of death from cancer. Cancer is the main reason for mortality worldwide, there were over than 8.3 million mortalities in 2012. Main types of cancer include: lung cancer (1.59 million deaths per year), liver cancer (74500 deaths per year), stomach (72300 deaths per year), colon (694000 deaths per year), breast cancer (521000 deaths per year) and esophageal cancer (400,000 deaths per year). Some of the most prevalent kinds of cancer such as breast, cervix, mouth and colon cancers, when diagnosed early and treated by best methods could have high therapeutic success. Some types of cancers including leukemia and lymphoma in children can have high improvement rate even after diffusion with proper treatments. Cancer treatment needs accurate selections of one or more of some interventions such as surgery, radiation therapy and chemotherapy. It comes with this goal that while improving the quality of life in the patient, it can also increase their life years through treating the disease (1) .
Radiation therapy as an important part of combination therapy of cancer has been considerably attended during recent decades; its philosophy includes attaining to higher and more effective dosages of radiation without increasing the prevalence of its complication (2) . For improving the clinical consequences of cancer, various radiotherapeutic methods are used including External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), 3-Dimensional Conformal Radiation Therapy (3D-CRT) and Intraoperative radiation therapy (IORT) (3) . One of these techniques which were mentioned above, called IORT, is a technique to deliver a high dose of radiation to a locally advanced tumor to protect the neighboring normal tissues at the time of surgery (3). During IORT, the normal tissues are not exposed to radiation because they are removed or shielded from the treatment field (4, 5) . Therefore, by the advent of the technology in Iran and considering the fact that recently there has been a high demand for reimbursing such a technology by insurance companies, this study aimed to review the safety, effectiveness and economic evaluation of IORT for the treatment of patients with different cancer types.
Methods
Scientific literature was searched in the main biomedical databases up to March 2014: Centre for Reviews and Dissemination (Health Technology Assessment, Database of Abstracts of Reviews of Effectiveness, and NHS Economic Evaluation Database), Cochrane Library and PubMed. Mesh and free text were used in the search strategy (Table 1) . Duplicated and nonrelevant studies were removed. The titles and abstracts of the remaining studies were investigated and unrelated studies were excluded. The full texts of the remaining articles were checked against the inclusion criteria to select studies for the review (Fig.  1) . Two independent reviewers checked the selected studies in accordance with inclusion criteria, with any disagreements being resolved by consensus. A structured form was used to collect data from the included studies. The criteria were as follows: (1) The study design, systematic reviews, meta-analysis, health technology assessment and economic evaluations; (2) Treatment type: patients who received intraoperative radiotherapy (IORT) or other prevalent methods used for radiotherapy; (3) Patient type: patient diagnosed with cancer in any stage; (4) Language: only publications in English or English abstracts were included; (5) Outcome: Overall survival, complications, expected life years, doses of irradiation, costs and surgical time were considered as outcome. Because this was a rapid review study, the quality of papers investigated in this study was not critically assessed; however, because the studied papers have been provided from Cochrane library and Centre for Reviews and Dissemination (CRD), it could be stated that these databases can provide highest level of quality for medical papers based on evi- dences. Finally, qualitative analysis was done using thematic synthesis. In this study, the search strategy was as Table 1 .
Results
Sixteen studies met the inclusion criteria and comprised 9 systematic reviews (2, 3, 6-12), one health technology assessment (13) , one literature review (14) , four economic evaluation (15-18) and one health technology horizon scanning (19). Two studies were published in 2014 (16, 18), three in 2013 (2, 10, 15), three in 2012 (3, 6, 13) , two in 2011 (8, 12), one in 2010 (17) , one in 2009 (7), one in 2008 (11) and three in 2004 (9, 14, 19) (Table 2) . Results were presented in six sub-categories including survival rate, complications, life expected years, irradiation rate, costs and surgical times. Also, included studies on the basis of cancer types were as follows: ten on breast cancer (2, 6, 7, 9, 12, 13, 15, 16, 18, 19) , three on colorectal cancer (7, 8, 10) , one on pancreatic cancer (11), one on pelvic gynecologic malignancies (14) , one on prostate cancer (3), one on liver cancer (17) . Table 2 reflects the main characteristics of the studies.
A-Safety A-1-Complications
In the study conducted by Cucins-Hearn et al. on using IORT in breast cancer, less complications after operation was reported; therefore, one cannot determine the relative Safety, effectiveness and economic evaluation of intra-operative radiation… safety and effectiveness of using IORT compared to BCT (9). Ruano-Ravina et al. concluded that there were less occurrence of chronic and acute complications when using combined therapy with IORT and EBRT for breast cancer in early stages (12). In a study, Cantero-Munoz et al. indicated that using IORT in treating breast cancer is a relatively safe method because its observed complication is similar to that of external radiotherapy (7) . In another study, Cantero-Munoz et al. concluded that acute complications from the use of IORT in colorectal cancer was mainly of gastrointestinal type, and IORT technology is a safe method with no increase in the toxicity resulted from conventional treatment (8). In another study by Cantero-Munoz et al. it was found that using IORT individually for breast cancer may not considerably improve the toxicity of conventional treatment (2). Mirnezami et al. did not report any increase in general side effects whether urologic or anastomotic when using IORT in colorectal cancer. Also, their results revealed that IORT may improve the onco- 
B-Effectiveness B-1-Survival Rate
Cuncins-Hearn et al. showed that shortterm outcomes for both treatment methods, IORT and Breast Conserving Therapy (BCT), in the early-stage breast cancer were similar in term of local recurrence, disease-free survival and overall survival. However, the existing evidence base for using IORT in early breast cancer is poor (9). Ruano-Ravina et al. found that IORT may cause a slight increase survival among patients with pancreatic cancer in localized stages. However, the results were not in favor of IORT in the case of pancreatic cancer in the locally advanced and metastatic stages (11). Bahadur et al. concluded that the difference in the overall survival, disease-free survival and disease-free distant survival among 4 interventions including External Beam Radiation Therapy (EBRT), High Dose Rate (HDR), IntensityModulated Radiation Therapy (IMRT) and IORT in breast cancer is not significant (6). Ruano-Ravina et al. found that in combined therapy with IORT and EBRT in early-stage breast cancer, local control was over 95% for 1 and 4 years of follow-up, and the 5-year overall survival was 99%. TARGIT-A(TARGeted Intraoperative radioTherapy Alone) study found a similar survival for IORT compared to standard treatment (12). Cantero-Munoz et al. indicated that using IORT in breast cancer causes slight improvement in their survival rate than patients treated by other treatments (7). Cantero-Munoz et al. in another study concluded that the use of IORT for colorectal cancer, five-to-six-year local control was over 80% and 5-year overall survival was close to 65%. For recurrences, the 5-year overall survival was 30%. Also, their study showed that adding IORT to conventional treatment reduces the incidence of local recurrences within the radiation area over 10%(8). In another study conducted to assess the effectiveness of IORT as a replacement treatment for current standard treatment of breast cancer, Cantero-Munoz et al. found that results from studies assessing the IORT as a replacement for a dosage promoting the external radiation indicate that this combination may not increase the effectiveness and overall survival. Using IORT individually may have recurrence and metastasis similar to conventional treatment (2). Mirnezami et al. concluded that using IORT in colorectal cancer may have a significant effect on improving the localized control, overall survival and disease-free survival (10). Australian Horizon scanning Report declared that according to the existing evidences, the safety and relative effectiveness of IORT to maintain the breast with post-operative radiation therapy has not been yet clear compared to surgery (19). Glujovsky et al. indicated that intra-operative radiation therapy in the gynecology cancers should be only considered in terms of clinical protocols and tests. Extended usage of this method may not be recommended in daily clinical practice. It seems that IORT may be potentially effective for patients with localized recurrence in their pelvic wall (14) . Xie et al. concluded that in breast cancer, the localized recurrence rate for inter-operative radiation therapy is similar to traditional treatments with external radiation therapy (13).
B-2-Life Expected Years
Esserman et al. found that in breast cancer, by using IORT during primary stages and with increase in the rate of localized recurrence of IORT more than 10% during 10 years, only less than 0.002 life expectancy (less than one day) can be expected compared to EBRT (16). Alvarado et al. in their study indicated that in early stages of Safety, effectiveness and economic evaluation of intra-operative radiation… 6 
B-3-Radiation Rate
Xie et al. concluded that using IORT in breast cancer may reduce the workload of oncological radiation team. In the patients' point of view, using IORT may considerably reduce the troubling weekly external radiation as well as waiting time for radiation therapy patients (13) . Lu indicated that using IORT in primary liver cancer may effectively protect from adjacent sensitive tissues with improving the dosage absorbed in the tumors as well as local control rate (17) .
C-Economic Evaluation C-1-Cost of Treatment
Xie et al. concluded that using single dosage IORT in breast cancer may slightly reduce or increase in the budget expenditures based on the patients' turnover (13) . Esserman et al. found that there will be an opportunity cost amounted to 1.7 billion USD for using IORT during a 5 year period for low risk females, hormone receptor-positive and postmenopausal females (16). Alvarado et al. indicated that single dosage IORT during operation in early stage breast cancer is considered as a dominated treatment with a more cost effective strategy by providing more life expectancy based on quality of living together with reduced costs compared to 6 weeks of administrating the WB-EBRT. Compared to WB-EBRT, IORT has lower cost and higher QALY with valuable strategy. IORT is an example of new technology with cost lower than existing treatment standard but with similar clinical effectiveness (15). Lu concluded that cost of using IORT in primary liver cancer is considerably lower than 3-Dimentional Conformal Radiation Therapy (3D-CRT) (17) . Shah et al. in their study indicated that for treating 1000 patients affected by breast cancer, the cost savings for using IORT compared to WB-3D-CRT, APBI-IMRT, APBI-SL, APBI-ML and APBI-I is 3.6-4.3 million dollars, 1.6-2.4 million dollars, 3.6 to 4.4 million dollars, 7.5 -8.2 million dollars and 2.8 to 3.6 million dollars, respectively and compared to APBI 3D-CRT, it saves costs up to 1.6 to 2.4 million dollars. The cost per QALY for WBI-3D CRT, APBI-IMRT, APBI-SL, APBI-ML and APBI-I compared to IORT was 47990 to 60002 dollars, 17335 to 29347 dollars, 49019 to 61031 dollars, 108162 to 120173 dollars and 36129 to 48141 dollars, respectively. According to the results of this study, APBI and WBI were cost-effective compared to IORT. They concluded that according to the analysis of costs minimization, IORT has the potential for cost savings in managing early-stage breast cancer; however, considering the additional medical and non-medical costs, WBI and APBI are cost-effective modalities based cost-per-QALY analyses and will be yet remained as standard of treatment (18).
C-2-Surgery Time
Xie et al. concluded that using IORT technology may result in increase of operation room load with increase in waiting time for surgery (13) . Marchioro et al. indicated that IOERT is considered as a method with acceptable surgery time (3).
Discussion
According to the studies, it seems that in this case, using this method for colorectal cancer could only significantly increase the survival rate with no significant effect on other types of cancer (6-8,10-12,15). Because of the complications of using this kind of radiation therapy, the studies generally focused on post-operative complications and toxicity from using intraoperative radiation therapy, and it seems that such complications are slight and this technology can be safely used in all types of cancer (2, 6-10, 12, 13, 16, 19) . For life expectancy, in breast cancer, if IORT localized recurrence rate was high about 10% per 10 years and IORT is applied in early stage of disease, we will expect 0.002 fewer life years (less than one day) compared to EBRT. Also, in primary stages of breast cancer, single dosage IORT is less effective compared to 6-week WB-EBRT, with the rate of 0.062 days (15, 16). By IORT, one can attack the site of neoplasm with higher accuracy without damaging the intact tissues by radiation (17, 19) . Studies indicate that using intra-operative radiation therapy may be potentially accounted as a costeffective strategy for controlling and managing breast cancer (15-17). Using IOERT may be conducted during an acceptable surgical time. However, this aspect has heterogeneity because it has also been pointed that using IORT technology may increase the load of operation room by increasing the waiting time for surgery operation (3, 13) . Based on the current level of evidence, that are the highest level of evidence on the Evidence Base Medicine pyramid for using intra-operative radiation therapy, it can be generally concluded that IORT is a relatively safe and cost-effective treatment method for managing the early-stage breast cancer and it can also significantly increase the survival of colorectal cancer patients. In addition, the results of this study have implications with respect to reimbursement of this technology. Given that the results of economic evaluation studies in other countries cannot be generalized to other contexts, an economic evaluation study on IORT needs to be undertaken in our country.
